• Bay Area Times
  • Posts
  • 2nd Alzheimer’s drug approved by FDA: donanemab (Kisunla) by Eli Lilly

2nd Alzheimer’s drug approved by FDA: donanemab (Kisunla) by Eli Lilly

 

Brought to you by**:

**Sponsored. Clicking on ad links may share your email with Mercury for remarketing purposes.

Top stories today:

  1. 2nd Alzheimer’s drug approved by FDA: donanemab (Kisunla) by Lilly
  2. Figma disables Make Design feature after it was found copying Apple
  3. Runway AI in talks to raise $450M at $4B valuation
  4. Tesla stock +10% after deliveries fall less than expected
  5. Exits for Europe’s VC-backed fintechs continue to decelerate

0. Data and calendar

All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).

All times are ET.

1. 2nd Alzheimer’s drug approved by FDA: donanemab (Kisunla) by Eli Lilly

22%-36% slowdown of clinical decline was observed in donanemab’s Phase 3 clinical trial:

2. Figma disables Make Design feature after it was found copying Apple’s designs

  • Figma says that they did not train their own models.

    • OpenAI’s GPT-4o and Amazon’s Titan Image Generator G1 are used instead.

  • “Soon”: when Make Designs will be re-enabled.

  • After five years of creating a powerful banking* experience loved by over 200K startups, Mercury is building upon that bank account with new products that power critical financial workflows.

  • Pay your bills more accurately with software that eliminates manual work — built right into your Mercury account.

  • Why send money to another platform to pay your bills? By eliminating third-party processing, you pay bills the moment you need to, allowing you to maximize your cash flow.

**Sponsored. Clicking on ad links may share your email with Mercury for remarketing purposes.

4. Runway AI in talks to raise $450M at $4B valuation

It would make the text-to-video AI firm the #10 most valuable generative AI startup:

Subscribe to keep reading

This content is free, but you must be subscribed to Bay Area Times to continue reading.

Already a subscriber?Sign In.Not now